BioCentury | Oct 11, 2010
Company News

Acea Biosciences, Vivo Biosciences deal

...assays for Acea's xCELLigence system. The new assays will use Vivo's HuBiogel technology, a human-derived biomatrix...
BioCentury | Jul 20, 2009
Company News

Pegasus Biologics, Synovis Life Technologies Inc. deal

...Pegasus' marketed products OrthAdapt Bioimplant, a type I collagen scaffold for tissue damage; and Unite Biomatrix...
BioCentury | Nov 22, 2004
Clinical News

BioMatrix cardiovascular data

...German and Brazilian STEALTH trial in 120 patients, angiographic analysis at 6 months showed the BioMatrix...
...compared to the bare metal stent group (3.9% vs. 7.7%, p=0.4). The analysis also showed Biomatrix...
...p<0.001). Intravascular ultrasound (IVUS) analysis showed the percent neointimal volume was significantly lower in the Biomatrix...
BioCentury | Nov 8, 2004
Company News

Genzyme, Wyeth sales and marketing update

...receive marketing approval in Japan next year. WYE obtained rights to Synvisc in 1997 from Biomatrix...
BioCentury | Nov 4, 2004
Company News

Genzyme to buy back Synvisc rights

...markets the drug in certain countries. In 1997, WYE gained rights to the compound from Biomatrix...
BioCentury | Jun 9, 2003
Finance

Ebb & Flow

...fair market value, which they put at $1.5-$2 billion. Riggs is the former president of Biomatrix...
BioCentury | Jun 9, 2003
Company News

Genzyme General Corp., Genzyme Biosurgery Inc. biopharmaceuticals news

...$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...
...maintain a tracking stock structure that would "protect the holders' interest in the value of Biomatrix's...
BioCentury | Jun 3, 2003
Top Story

GZBX consolidation opposed

...$1.5-$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...
BioCentury | May 12, 2003
Finance

Family values

...rose 32% to $26.4 million from the first quarter of 2002. Synvisc was developed by Biomatrix...
...March 2000 to form GZBX (see BioCentury, March 13, 2000) . That deal initially valued Biomatrix...
...ever since. GENZ estimates it spent about $476 million in cash and stock to acquire Biomatrix...
BioCentury | Dec 4, 2000
Company News

Biomatrix, Farmila Farmaceutici Milano S.p.A. sales and marketing update

...exclusive license in the territory for two years, markets the products under its Hyalogen label. Biomatrix Inc....
Items per page:
1 - 10 of 93
BioCentury | Oct 11, 2010
Company News

Acea Biosciences, Vivo Biosciences deal

...assays for Acea's xCELLigence system. The new assays will use Vivo's HuBiogel technology, a human-derived biomatrix...
BioCentury | Jul 20, 2009
Company News

Pegasus Biologics, Synovis Life Technologies Inc. deal

...Pegasus' marketed products OrthAdapt Bioimplant, a type I collagen scaffold for tissue damage; and Unite Biomatrix...
BioCentury | Nov 22, 2004
Clinical News

BioMatrix cardiovascular data

...German and Brazilian STEALTH trial in 120 patients, angiographic analysis at 6 months showed the BioMatrix...
...compared to the bare metal stent group (3.9% vs. 7.7%, p=0.4). The analysis also showed Biomatrix...
...p<0.001). Intravascular ultrasound (IVUS) analysis showed the percent neointimal volume was significantly lower in the Biomatrix...
BioCentury | Nov 8, 2004
Company News

Genzyme, Wyeth sales and marketing update

...receive marketing approval in Japan next year. WYE obtained rights to Synvisc in 1997 from Biomatrix...
BioCentury | Nov 4, 2004
Company News

Genzyme to buy back Synvisc rights

...markets the drug in certain countries. In 1997, WYE gained rights to the compound from Biomatrix...
BioCentury | Jun 9, 2003
Finance

Ebb & Flow

...fair market value, which they put at $1.5-$2 billion. Riggs is the former president of Biomatrix...
BioCentury | Jun 9, 2003
Company News

Genzyme General Corp., Genzyme Biosurgery Inc. biopharmaceuticals news

...$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...
...maintain a tracking stock structure that would "protect the holders' interest in the value of Biomatrix's...
BioCentury | Jun 3, 2003
Top Story

GZBX consolidation opposed

...$1.5-$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...
BioCentury | May 12, 2003
Finance

Family values

...rose 32% to $26.4 million from the first quarter of 2002. Synvisc was developed by Biomatrix...
...March 2000 to form GZBX (see BioCentury, March 13, 2000) . That deal initially valued Biomatrix...
...ever since. GENZ estimates it spent about $476 million in cash and stock to acquire Biomatrix...
BioCentury | Dec 4, 2000
Company News

Biomatrix, Farmila Farmaceutici Milano S.p.A. sales and marketing update

...exclusive license in the territory for two years, markets the products under its Hyalogen label. Biomatrix Inc....
Items per page:
1 - 10 of 93